Screening– tag –
-
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
AI Transforms Drug Discovery: Generative AI Accelerates Molecule Design to Clinical Prediction, Reducing R&D Costs and Risks
World Pharma Today Unknown Overview AI, particularly generative AI, is fundamentally transforming drug discovery in 2026 by accelerating target identification, molecule design, and outcome prediction. AI-driven platforms computationally ... -
ChemRxiv Unveils AI Workflow for Structure-Aware Small-Molecule Drug Design: Integrating Agentic, Explainable, and Generative AI for Design to Prioritization
ChemRxiv Unknown Overview A preprint on ChemRxiv describes an innovative AI workflow for structure-aware small-molecule drug design, integrating agentic and explainable machine learning with generative molecular design. This system autom... -
Organoid Research Showcased at ISSCR 2026: iPSC and Adult Stem Cell-Derived Systems Drive Breakthroughs in Organogenesis and Disease Modeling
International Society for Stem Cell Research (ISSCR) International Overview The ISSCR 2026 annual meeting highlighted the latest innovations and technical advancements in organoid technology, particularly emphasizing iPSC and adult stem ... -
Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization
Chivanta Unknown Overview The greatest challenge in commercializing CAR-T cell therapies is not solely manufacturing capacity but also the hospital infrastructure and the overall treatment process. Clinical operational bottlenecks, speci... -
VCU-Led Team Develops Novel Cancer Drug Discovery Platform Leveraging 3D Bioprinting and AI for Rapid Therapy Identification
VCU Massey Comprehensive Cancer Center USA Overview A scientific team from VCU Massey Comprehensive Cancer Center, UCLA Health Jonsson Comprehensive Cancer Center, and the University of Colorado School of Medicine has developed a new pla... -
AI Accelerates Early Drug Discovery, But Patient Outcomes Remain the Ultimate Validation
MedCity News USA Overview Artificial intelligence is proving highly effective in accelerating early-stage drug discovery, with AI-designed candidates showing promising success rates in Phase 1 clinical trials. However, the ultimate value... -
AI Significantly Reduces Drug Discovery Space: De Novo Protein Design and Bruker’s Data Platform Accelerate Innovation
Temple 8 Unknown Overview AI models are drastically reducing the biological exploration space in drug discovery by screening billions of virtual molecules in seconds, predicting binding affinities, and optimizing pharmacokinetic properti... -
McKinsey Report: Generative AI and Foundation Models Revolutionize Biopharma R&D Workflow, Accelerating Molecular Design and Antibody Engineering
McKinsey Unknown Overview A McKinsey report highlights that generative AI and foundation models are revolutionizing biopharma R&D workflows. These AI models design novel molecular structures, experimental hypotheses, and synthetic pa... -
Foundation Models and Generative AI Reshape Molecular Science: Data-Centric Learning Boosts Virtual Screening Accuracy and Molecular Generation Control
Curate ND USA Overview Foundation models and generative AI are transforming molecular prediction, exploration, and design across chemistry, biology, and materials science. This research developed data-centric learning methods and molecul...
